PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY IN THE BIOLOGIC ERA: IMPLICATIONS FOR PRACTICE

Supplement 2 to Volume 78

November 2011

www.ccjm.org/content/78/Suppl_2

Supplement Editor

LEONARD CALABRESE, DO Cleveland Clinic

Contents

Introduction S Leonard Calabrese, DO	52
History and current concepts in the pathogenesis of PML	53
The clinical features of PML Joseph R. Berger, MD	58
Pharmacovigilance and PML in the oncology setting	13
Multiple sclerosis, natalizumab, and PML: Helping patients decide	18
HIV-associated PML: Changing epidemiology and clinical approach	24
PML and rheumatology: The contribution of disease and drugs	28
Advances in the management of PML: Focus on natalizumab	33
A rational approach to PML for the clinician	38

Copyright © 2011 The Cleveland Clinic Foundation. All rights reserved.

The statements and opinions expressed in this supplement to Cleveland Clinic Journal of Medicine are those of the authors and not necessarily those of The Cleveland Clinic Foundation, its Board of Trustees, or Genentech. They do not necessarily represent formal practice guidelines in effect at Cleveland Clinic.

 $\label{lem:closed} \textit{Cleveland Clinic Journal of Medicine} \ [ISSN 0891-1150 (print), ISSN 1939-2869 (online)] is published 12 times yearly by The Cleveland Clinic Foundation.$

Subscription rates: U.S. and possessions: personal \$115; institutional \$143; single copy/

back issue \$20. Foreign: \$160; single copy/back issue \$20. Institutional (multiple-reader) rate applies to libraries, schools, hospitals, and federal, commercial, and private organizations. Individual subscriptions must be in the names of and paid by individuals.

Postmaster address changes: Cleveland Clinic Journal of Medicine, 9500 Euclid Avenue, TR4-04, Cleveland, OH 44195. Subscription orders, editorial, reprint, and production offices (same address): 216-444-2661 (phone); 216-444-9385 (fax); ccjm@ccf.org (e-mail); www.ccjm.org (Web).

Printed in USA.